Chimeric Therapeutics Ltd. (AU:CHM) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Chimeric Therapeutics has successfully completed the dose-finding phase of their ADVENT-AML Phase 1B clinical trial, marking a significant step forward in the treatment of Acute Myeloid Leukemia. This trial explores the innovative use of CORE NK cell therapy in combination with standard treatments, offering new hope for elderly and transplant-ineligible patients. With promising safety results, the trial is set to progress by enrolling more patients with newly diagnosed AML.
For further insights into AU:CHM stock, check out TipRanks’ Stock Analysis page.